The anti-tubercular drug delamanid as a potential oral treatment for visceral leishmaniasis

The anti-tubercular drug delamanid as a potential oral treatment for visceral leishmaniasis

There is an urgent requirement for safe, oral and cost-effective drugs for the treatment of visceral leishmaniasis (VL). We report that delamanid (OPC-67683), an approved drug for multi-drug resistant tuberculosis, is a potent inhibitor of Leishmania donovani both in vitro and in vivo. Twice-daily o...

Full description

Bibliographic Details
Main Authors: Stephen Patterson, Susan Wyllie, Suzanne Norval, Laste Stojanovski, Frederick RC Simeons, Jennifer L Auer, Maria Osuna-Cabello, Kevin D Read, Alan H Fairlamb
Format: Article
Language:English
Published: eLife Sciences Publications Ltd 2016-05-01
Series:eLife
Subjects:
Leishmania donovani
Visceral leishmaniasis
drug repurposing
pharmacokinetics
pharmacodynamics
OPC-67683
Online Access:https://elifesciences.org/articles/09744

Internet

https://elifesciences.org/articles/09744

Similar Items